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This study verified the correlation between the serum levels of TNF alpha and different clinical forms of tuberculosis.
We described a group of 24 patients presenting several clinical forms of tuberculosis and a control group of 13
healthy individuals. The levels of TNF alpha were measured by bioassay method. The levels of TNF-alpha had
significant differences between the tuberculosis and control groups. The patients with abnormal chest X-Ray
findings had higher TNF alpha levels (15328.48 ± 4602.19 pg/mL) when compared to patients with normal X-Rays
(3353.18 ± 1495.29 pg/mL) (p<0.05). Patients that lost weight had higher TNF alpha levels (15468.54 ± 4580.54 pg/
mL) than those that didn’t loose weight (2904.98 ± 1367.89) (p<0.05). The levels of TNF alpha were higher in
patients with a positive PPD skin test than in those with a negative PPD test (p<0.05). There was a positive
correlation between patients’ clinical severity and the serum levels of TNF alpha. In patients with successive
measurements of TNF alpha, we observed that there was a drop in cytokine levels, and also a clinical improvement
concomitantly. We concluded that there was a correlation between serum TNF alpha levels and chest X-Ray alterations,
loss of weight, positive PPD skin test and clinical severity in patients with tuberculosis. There was evidence of a
worse clinical outcome in patients with tuberculosis that presented higher TNF alpha serum levels.
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Abbreviations: TNF=tumor necrosis factor, TB=tuberculosis, M. tuberculosis=Mycobacterium tuberculosis,
IL=interleukin, CTLs=cytotoxic T lymphocytes, MHC=major histocompatibility complex, IFN=interferon,
BAL=bronchoalveolar lavage, CT=computed tomographic, ADA=adenosine deaminase.
The pathogenesis of the inflammatory response in
tuberculosis (TB), involving mainly cellular and molecular
phenomena, remains unclear. Macrophage activation,
phagocytosis mechanisms, and the survival of Mycobacterium
tuberculosis in phagocytic vesicles must be further studied.
When tuberculosis infection occurs, a variety of
chemokines and cytokines are secreted from infected cells
and tissue macrophages. TNF alpha increases early in the
disease and takes part in the pathogenesis and prevention of
mycobacterial infection. TNF alpha also appears crucial for
the formation of M. tuberculosis-constraining granulomas,
infection control and elimination of mycobacteria [1]. The
production of TNF alpha in HIV-TB co-infected patients is
down-regulated in T lymphocytes, and this may explain the
cause of defective granuloma formation in this condition [2].
Serum levels of TNF alpha and IL-1 are proportional to the
degree of tissue infection [3] and are also associated with
induction of fever and other consumptive manifestations of
the disease [4].
The cellular immune response is essential for TB
resistance, mainly through cytokine production such as IL-
12, IL-18, IFN gamma, IL-2 and TNF alpha. The TCD8+ cells
(CTLs) perform cytotoxic actions, mainly through major
histocompatibility complex (MHC) class I molecules that, in
association with CD1d molecules, present glycolipid antigens
to T lymphocyte cells [5]. CTL cells may have a protective
role in TB disease due to several mechanisms: 1) producing
potent antibacterial cytokines such as IFN gamma and TNF
alpha; 2) recognizing M. tuberculosis antigens presented by
MHC associated to HLA-I complex; 3) inducing apoptosis in
infected cells [6,7].
The role of cytokines produced by Th1/Th2 lymphocytes
is complex due to the action of IL-12, IFN gamma, IL-4 and IL-
10 (pro-inflammatory and anti-inflammatory cytokines). Several
aspects of this complex interaction have been studied in recent
studies: a) IFN gamma inhibition by IL-10 [8]; b) IFN gamma
and IL-10 production stimulated by IL-12 [9]; c) IFN gamma
and IL-10 production stimulated by TCD4+ clones in the
bronchoalveolar lavage (BAL) fluid of patients with pulmonary
TB [10]; d) Th2 cytokine association with histopathologic
alterations in patients with TB [11].
Several studies have shown physiopathologic correlation
between serum TNF alpha and the evolutive course of
mycobacteria infection. TNF alpha neutralization caused an
increase in pulmonary bacterial load in mice that had been
infected with M. tuberculosis six months before [12]. There is
an association between TNF alpha production and
M.tuberculosis virulence in human monocytes, as well as a
correlation between the increase in serum TNF alpha levels
and the clinical deterioration in patients with a severe form of
TB [13,14]. In vitro studies of IFN-γ, IL-4, TGF-β, and IL-1β
produced by peripheral blood mononuclear cells from
tuberculosis patients [15], as well as reports wherein analysis
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of TNF alpha concentrations in BAL fluid [16] showed that
the greater the amount of lung involvement the higher the
cytokine production.
We report 24 patients with several TB clinical forms where
sera measurements of TNF alpha had been made. We tried to
associate serum TNF alpha levels with the evolution of clinical
forms of TB. We concluded that serum TNF alpha measurement
might play an important role in the evaluation of the
inflammatory phenomena in TB.
Material and Methods
Sera were obtained from 24 patients, from the Infectious
Diseases Clinic and Internal Medicine Clinic of the Hospital
das Clínicas da Faculdade de Medicina da Universidade de
São Paulo, with active TB and from 13 healthy individuals
(control group). TB patients had a mean age of 32.95 years (18
to 72 years) with six females and eighteen males. The control
group had a mean age of 34.84 years (21 to 47 years) with four
males and nine females. Informed consent was obtained from
each patient and the protocol for the research project was
approved by the Ethics Committee of the Institution. We
described 24 TB patients having the following clinical forms:
14 pulmonary, 2 pleural - pulmonary, 1 pleural - pulmonary +
pericardial, 1 pleural + lymphatic, 1 pulmonary + lymphatic, 1
disseminated, 1 miliary, 2 peritoneal, 1 cutaneous + pulmonary.
The TB diagnoses were established between 1993 and 2002.
Patients were all HIV negative and they were receiving
anti-tuberculous therapy at the time of blood sampling.
Medical records of all patients were analyzed for clinical data
such as anemia, fever, weight loss, dyspnea, night sweats,
cough, sputum, as well as diagnostic tests such as thoracic
X-Ray (XR), computed tomographic (CT) scan of the chest,
PPD skin test, erythrocyte sedimentation rate, and blood
counts. The TB diagnosis was made if acid-fast bacilli had
been positive in search or culture in each case (Table 2). We
considered anemia as hemoglobin < 12 g/dL (woman) or <
14g/dL (man). Fever was defined as temperature ≥ 38°C. The
clinical variables weight loss, dyspnea, night sweats, cough
and sputum were registered as 0 (absent) or 1 (present). The
results of the thoracic radiograph, the computed tomographic
(CT) scan of the chest, and the sedimentation rate, were coded
as 0 (normal) or 1 (altered). The PPD skin test was coded as 0
(negative) or 1 (positive). We also evaluated whether tissue
destruction was detected by image diagnostic methods. The
clinical severity of each case was determined through the
following score: thoracic XR/CT normal=0; thoracic XR/CT
altered without cavity=1; thoracic XR/CT altered with
cavity=2; without anemia=0; with anemia=1; without
hypoxia=0; with hypoxia=1; without weight loss=0; with
weight loss=1.
TNF alpha Assay
TNF alpha bioactivity was determined by the McGee &
Clemens bioassay method [17] with modifications, using L929
cells as targets. Briefly, L929 cells were cultured for 24 hours
on flat-bottom 96-well plates (1 x 104 cells/well), with RPMI
1640 medium at 37o C under an atmosphere of 5% CO2 and
95% air. L929 cell monolayers were pre-incubated for 2 hours
with 1 mg/mL of Actinomycin D (ActD). The patient’s sera
(stored at -80ºC) were added to the wells and incubated for 18
hours. After this, the cells were stained with MTT vital stain.
All samples were assayed at the same time. The readings were
done using a spectrophotometer plate reader at a wavelength
of 540 nm. The cell viability percentage was calculated using
the formula: % cell viability=optical density (samples)/optical
density (control) x 100. The final results of each sample were
obtained through the average of eight wells. The serum TNF
alpha level was calculated through a standard curve
(recombinant TNF alpha versus cell viability percentage). The
confidence interval over 95% of the control group (UCI 95%)
was considered as the cut-off between individuals in the
controls and individuals with TB.
Statistical Analysis
The data were separated into categorical and continuous
variables. The categorical values were expressed in absolute
frequency (n) and relative frequency (%), using Pearson Chi-
square test. The continuous and semi continuous variables
were compared to a normal curve, and classified as parametric
or not using the K-S test. TNF alpha values were categorized
using the superior 95% confidence interval. The parametric
data were shown as mean ± standard error, and compared
using the unpaired Student’s t-test. The nonparametric data
were shown as median and 25th – 75th percentiles, and compared
using the Mann-Whitney test. The ROC curve was used as
the operational response curve to establish whether TNF alpha
had good discriminating power. The correlations between the
TNF alpha level in each case and all clinical and diagnostic
variables were evaluated through the r-value calculation using
Pearson’s correlation. The alpha risk for all conditions was
≤5% in type I error, and ≤ 20% for beta risk in type II error.
Results
Demographic and Clinical Characteristics
The demographic data and TNF alpha levels of the 13
subject control group are shown in Table 1. The patients’
general characteristics, TB clinical forms, length of symptoms
and serum TNF alpha levels are shown in the Table 2. The
days of therapy, clinical complications, length of treatment
and clinical evolution of the patients with the TNF alpha levels
are shown in Table 3. The mean of serum TNF alpha levels in
patients with active TB was 13035.54 ± 15948.35 pg/mL, which
was significantly higher than those found in healthy control
individuals (341.3 ± 127.1 pg/mL) (p < 0.01).
Aspects of Severity and Evolution of Tuberculosis
The patients’ distribution for clinical severity score is
shown in Table 4. There was a positive correlation between
the clinical severity score and the serum TNF alpha level
(r=0.44; p=0.045) (Figure 1).
TNF-α and Severity TB
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Correlation Between Clinical or Laboratorial Variables and
TNF Values
Table 5 shows statistical comparisons between clinical
and laboratory variables of TB patients. There were no
statistically significant differences between TNF alpha level
and the following variables: anemia (p=0.148), fever (p=0.475),
night sweats (p=0.859), dyspnea (p=0.514), cough (p=0.678)
and sputum (p=0.182). Only the weight loss variable showed
significant statistical difference in relation to TNF alpha. The
patients with weight loss had higher serum TNF alpha
(15468.54 ± 4580.54 pg/mL) than those without weight loss
(2904.98 ± 1367.89 pg/mL) (p<0.05). The patients with abnormal
chest X-rays had higher levels of TNF alpha (15328.48 ±
4602.19 pg/mL) in relation to the patients with normal chest X-
ray (3353.18 ± 1495.29 pg/mL) (p<0.05). There was no
difference between TNF alpha and sedimentation rate
(p=0.848), tissue destruction (p=0.149), multidrug-resistant TB
(p=0.695) and clinical survival (p=0.352). The serum TNF alpha
level was higher in patients with a positive PPD skin test
when compared to those with a negative PPD test (p<0.05).
TB treatment reduced significantly the serum TNF alpha values
(p<0.05). A positive correlation was found between treatment
duration and acid-fast bacilli (AFB) absence (r=0.717;  p<0.05).
In patients with successive TNF alpha measurements, a clinical
improvement was always observed when serum TNF alpha
levels dropped (patients 3, 7, 10, 14 and 19).
On the other hand, many patients without a decrease in
serum TNF alpha levels presented clinical problems during
their clinical evolution. For instance, patients 1 and 4 had
pulmonary giant bubbles, patient 6 (MDR-TB) developed
pulmonary cavitations, and patient 8 remained AFB positive
in sputum until the fifth month of TB therapy.
The highest serum TNF alpha levels (> 15 x normal) were
observed in 6 patients with severe TB: patient 1 (pulmonary
TB with bubbles), patient 3 (pulmonary TB with cavitations),
patient 4 (pulmonary TB with bubbles), patient 5 (pulmonary
- MDR TB), patient 10 (pulmonary - interstitial TB) and patient
19 (disseminated TB). We found that high serum TNF alpha
levels were associated with TB clinical forms having increased
tissue destruction (shown by image methods). In three patients
(15, 16 and 17), with pleural-pulmonary TB, high serum levels
of TNF alpha were noted. In these patients the concomitant
TNF alpha level in pleural fluid was undetectable.
The serum TNF alpha levels had good discriminant power
in identifying patients with Tuberculosis (n=24) from control
individuals (n=13). The control group upper confidence
interval of 95% (UCI 95%) was 618.1 pg/mL. This value was
used to categorize the continuous data. The ROC curve
showed that the TNF alpha test was reliable (area=0.908 ±
0.049, and p < 0.0001).
Discussion
We studied 24 patients with various TB clinical forms. We
tried to show a possible role of TNF alpha as a cytotoxic
agent, mainly when high serum levels were observed (patients
1, 3, 5, 4, 10, 14 and 19). The presence of TNF alpha in the
peripheral blood is a consequence of cytokine leakage to the
serum. This cytokine is produced by tissues and inflammatory
cells through monocyte-macrophage activation after M.
tuberculosis stimulation [18].
The groups of patients presented illustrate the TNF alpha
role in the various TB clinical forms. There was a marked
difference of serum TNF alpha levels between the TB group
and the control group. When the cases were classified by
clinical severity score, we observed a positive correlation
between clinical severity and serum TNF alpha levels. The
subgroup analysis also showed interesting results. The
MDR-TB cases (patients 5, 6, 7) presented severe
pulmonary lesions with increased tissue destruction. In
this group, the serum TNF alpha level ranged from a slight
elevation (patients 6 and 7), to a very high level (patient 5).
Table 1. Demographic characteristics of subject control group
and TNF alpha levels.
Figure 1. Positive correlation between serum TNF-alpha levels
and the clinical severity score.
TNF-α and Severity TB
Control Age Sex TNF alpha
(pg/mL)
1 27 F 1,415
2 35 F 0.49
3 21 M 8
4 40 M 45
5 40 F 314
6 48 F 598
7 41 F 389
8 50 F 314
9 37 F 133
10 32 F 15
11 35 F 45
12 31 M 1,141
13 53 M 19
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Table 2. Demographic and clinical characteristics of patients with tuberculosis and TNF alpha levels.
On the other hand, in three patients the serum TNF alpha
was undetectable: patient 9 (pulmonary with cavitations
TB), patient 12 (pulmonary TB), and patient 21 (miliary TB).
Patient 21 had a negative PPD skin test. We speculate that
in these patients the immune response to the infectious
agent could have been very weak. In another two patients,
normal serum TNF alpha levels were detected: patient 18
(pleural + lymphatic TB) and patient 20 (lymphatic +
pulmonary TB). These patients had normal serum TNF
alpha values in spite of the presence of extensive
lymphadenopathy with necrosis detected using image
methods. We suppose that there can be a
compartmentalization of the immune response in some
patients with lymphatic TB. Patients 1, 3, 4, and 5 showed
the highest serum TNF alpha levels and they also had
increased pulmonary tissue destruction. We suggest that
TNF alpha may have a direct role in this phenomenon.
We quantified TNF alpha successively in 10 patients and
observed that, when serum TNF alpha levels decreased during
clinical evolution (patients 3, 7, 10, 14 and 19), a clinical
improvement was always noted. In contrast, when serum TNF
alpha levels did not decrease during the evolution, a bad
clinical course was noted. These results indicate that the serum
TNF alpha level may be a good marker to predict the TB
patient’s clinical evolution. Ribeiro-Rodrigues et al. [19]
showed that decreases in sputum IFN-γ, TNF alpha, and IL-8
closely parallel and even precede mycobacterial clearance, and
they concluded that these cytokines may be markers of disease
activity and inflammation in TB.
In this study we also found a positive correlation between
serum TNF alpha levels and weight loss, abnormal chest X-
Rays and positive PPD skin tests. The positive correlation
between weight loss and serum TNF alpha levels was also
observed in other studies. Bossola et al. [20] showed that
TNF-α and Severity TB
Cases Age Sex Clinical form Symptoms length TB diagnosis TNF alpha*
1 40 M Pulmonary 12 months AFB† S + C‡ in sputum 27319.0 ± 4962.4 (4)
2 28 F Pulmonary 2 weeks AFB S + C in sputum 9055.0 (1)
3 50 M Pulmonary 6 months AFB S + C in BAL§ 14006.9 ± 19431.4 (2)
4 18 M Pulmonary 2 months AFB S + C in sputum 20328.0 ± 3920.2 (2)
5 20 F Pulmonary 4 months AFB S + C in sputum 56840.0 (1)
6 20 F Pulmonary 2 months AFB S + C in sputum 1551.4 ± 450.5 (2)
7 31 F Pulmonary 12 months AFB S + C in sputum 719.5 ± 615.9 (2)
8 27 M Pulmonary 6 months AFB S + C in sputum 1273.5 ± 224.1 (2)
9 47 M Pulmonary 12 months AFB S + C in sputum 0 ¦ (1)
10 61 M Pulmonary 6 months Lung biopsy 30221.0 ± 22600.5 (2)
11 72 M Pulmonary 2 months AFB S + C in BAL 865.2 (1)
12 19 M Pulmonary 4 months AFB S + C in BAL 0 (1)
13 24 M Pulmonary 2 months AFB S + C in sputum 966.2 ± 142.9 (2)
14 62 M Pulmonary 2 weeks AFB S + C in BAL 8620.0 ± 5987.8 (2)
15 32 M Pleural–pulmonary 2 months AFB S + C in pleural 9055.6 (1)
fluid
16 20 M Pleural-pulmonary 1 month AFB S + C in pleural 1519.9 (1)
biopsy
17 19 M Pleural-pulmonary + 5 months AFB S + C in pleural 2848.0 (1)
pericardial biopsy
18 21 M Pleural + lymphatic 2 months AFB S + C in 187.4 (1)
lymph node biopsy
19 24 M Disseminated ¶ 2 months AFB S + C in 45703.0 ± 5465.9 (2)
lymph node biopsy
20 21 F Lymphatic + 3 months AFB S + C in BAL and 303.9 (1)
pulmonary lymph node biopsy
21 32 F Miliary 15 days AFB C in sputum 0 (1)
22 50 M Peritoneal 18 months AFB C in ascitic fluid 3162.3 (1)
+ peritoneal biopsy
23 23 M Peritoneal 4 months Peritoneal biopsy 5000.0 (1)
24 30 M Cutaneous + 12 months AFB S + C in sputum 8112.3 (1)
pulmonary and skin abscess
* TNF alpha values are in pg/mL; Normal TNF alpha=618.1 pg/mL; Number of dosages are in parenthesis; †=acid-fast bacilli; ‡=search + culture;
§=bronchoalveolar lavage; ¦=TNF alpha undetectable; ¶=pulmonary, pleural, lymphatic, splenic and meningeal tuberculosis.
www.bjid.com.br
230 BJID 2008; 12 (June)
Table 3. Severity data and evolution aspects of patients with tuberculosis and levels of TNF-alpha.
serum TNF alpha concentrations were significantly higher in
patients with cancer and severe weight loss when compared
with patients having cancer and low weight loss. Cakir et al.
[21] speculated that serum TNF alpha levels and leptin might
be responsible for the weight loss in pulmonary tuberculosis
patients. Another study also correlated the chronic
administration of TNF alpha with weight loss in rats [22].
We observed that the patients with abnormal chest X-
rays had higher serum levels of TNF alpha. Tsao et al. showed
that the bronchoalveolar lavage fluid levels of TNF alpha, IL-
1β and IL-6 were all significantly higher in patients with large
cavities than in patients without cavities or with smaller
cavities [23,24] These authors also showed that the relative
excess of both TNF alpha and IL-1β, associated with soluble
TNF-α and Severity TB
Cases TNF-alpha Days of Clinical complications Therapeutic scheme Final evolution
(pg/mL) therapy
1 20000.0 90 Giant bubbles with pulmonary HRZ/6 months Recovery
28480.0 120 emphysema
30398.0 141
30398.0 183
2 9055.0 21 Cavitation in the left lung HRZ/8 days Recovery
ESZ/6 months
3 27747.0 30 A big cavitation in the HRZ/6 months Recovery
266.8 60 right upper lobe
4 17556.0 15 Giant bubbles in the right lung/ HRZ/6 months Death
23100.0 30 chronic hypoxia
5 56840.0 15 MDR - TB*, volumetric reduction of SHRZ/9 months Death
the left lung and bronchiectasis ECRZ/3 months
6 1232.8 6 MDR - TB; Cavitations and HRZ/2 months Recovery
1870.0 42 bronchiectasis in both lungs ESC+/6 months
7 1155.0 2 MDR - TB; Cavitations in both lungs HRZ/3 months Recovery
284.0 21 IHCCA/6 months
8 1115.0 150 None HRZ/6 months Recovery
1432.0 171
9 1000 30 Volumetric lung reduction and HRZ/6 months Recovery
cavitations in both lungs
10 46202.0 12 None HRZ/6 months Recovery
14240.0 19
11 865.2 4 None HRZ/6 months Recovery
12 0 2 None HRZ/6 months Recovery
13 865.2 15 Thrombocytopenia HRZ/15 days Recovery
1067.3 19 EES/6 months
14 12854.0 34 None HRZ/6 months Recovery
4386.0 61
15 9055.6 1 Respiratory failure HRZ/2 days Death
16 1519.9 1 None HRZ/6 months Recovery
17 2848.0 45 Pericardial effusion HRZ/6 months Recovery
18 187.4 30 Simultaneous Paracoccidioido-mycosis HRZ/6 months Recovery
19 49568.0 4 Necrosis in several tissues HRZ/6 months Recovery
41838.0 44
20 303.9 5 None HRZ/6 months Recovery
21 0 1 AgHBs+, AgHBe+, Anti-VHC+ HRZ/6 months Recovery
22 3162.3 38 Ascites HRZ/6 months Recovery
23 5000.0 1 Ascites HRZ/6 months Recovery
24 8112.3 1 Skin nodules in chest, neck, legs HRZ/4 days Death
and head with spontaneous leakage
HRZ: H=isoniazid, R=rifampin and Z=pyrazinamide; *=multidrug-resistant tuberculosis; ESC: E=ethambutol, S=streptomycin and
CIP=ciprofloxacin; HCCA: H=isoniazid, CFZ=clofazimine, CIP=ciprofloxacin and AKC=amikacin; EES: E=ethambutol, ETH=ethionamide
and S=streptomycin; ESZ: E=ethambutol, S=streptomycin and Z=pyrazinamide; SHRZ: S=streptomycin, H=isoniazid, R=rifampin and
Z=pyrazinamide; ECRZ: E=ethambutol, CIP=ciprofloxacin, ROX=roxythromicin and Z=pyrazinamide.
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Table 4. Distribution of the Tuberculosis patients by clinical severity score and serum TNF-alpha levels.
TNF alpha-receptor secretion imbalance, could have a
correlation with the pulmonary cavities in patients having
active TB [24]. However, there were few studies in medical
literature about the correlation between serum TNF alpha
levels and abnormal X-Rays, and further studies are necessary
to understand this phenomenon. We also found that the serum
TNF alpha level was elevated in patients with a positive PPD
skin test. Chu et al. [25] observed that the number of cells
staining for TNF alpha and IL-1 in the skin of six normal
individuals during the PPD – induced reaction persisted at
elevated levels [25]. The authors speculated that TNF alpha
might play an important role in the development of delayed-
type hypersensitivity in man. Therefore, we added the
information that a high serum TNF alpha level occurs in
patients with positive PPD skin tests, and this phenomenon
suggests a possible correlation between this cytokine serum
level and its tissue action.
We described three cases with pleural-pulmonary TB (15,
16 and 17) in which a high serum TNF alpha level was observed
without a concomitant increase of TNF alpha in the pleural
fluid. Vankayalapati et al. [26] reported that IL-18 and IFN
gamma concentrations are higher in the pleural fluid of TB
patients than in patients with other diseases. In another study,
pleural fluid TNF alpha levels and pleural fluid/serum TNF
alpha were higher in tuberculous effusions than in other
exudates, but their diagnostic value appears to be poorer than
that of ADA [27]. Our result differs from these studies [26,27]
and we did not find a clear explanation. We speculate that
there was a barrier separating the pleural fluid and the host’s
immune response due to pleural fibrosis present in patient 16.
We observed that in three cases, 1, 19 and 14, the serum TNF
alpha level increased after the treatment of TB began. However,
we can not state whether there was concomitant clinical
worsening in these cases. Bekker et al. [13] observed worsening
of clinical condition in 16 patients during the first 42 days of
treatment, with two deaths among those having severe
pulmonary TB. All patients had increased serum TNF alpha
and lactic acid levels. These authors associated the worsening
clinical condition of these patients with the increase of serum
TNF alpha levels. Such evidences show the importance of
estimating the serum cytokine level at the beginning of TB
treatment.
The relation between TNF alpha and TB stands out due to
the reactivation of latent TB infection with treatment with
tumor necrosis factor (TNF) antagonists [28] in patients with
several diseases such as: rheumatoid arthritis [29], juvenile
arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis,
glomerulonephritis, sarcoidosis and Behcet’s disease. These
diseases are characterized by a Th1 type immune response
associated with excess generation of TNF-alpha [30].
TNF-α and Severity TB
Cases Thoracic Anemia Hypoxia Weight loss Clinical TNF alpha*
X-Ray/CT severity score
1 2 1 1 1 5 27319.0 ± 4962.4 (4)
4 2 1 1 1 5 20328.0 ± 3920.2 (2)
3 2 1 1 1 5 14006.9 ± 19431.4 (2)
5 2 1 1 1 5 56840.0 (1)
9 2 1 1 1 5 1000 (1)
2 2 1 0 1 4 9055.0 (1)
6 2 1 0 1 4 1551.4 ± 450.5 (2)
7 2 1 0 1 4 719.5 ± 615.9 (2)
14 1 1 1 1 4 8620.0 ± 5987.8 (2)
20 1 1 1 1 4 303.9 (1)
8 1 1 0 1 3 1273.5 ± 224.1 (2)
10 1 1 0 1 3 30221.0 ± 22600.5 (2)
15 1 0 1 1 3 9055.6 (1)
17 1 1 0 1 3 2848.0 (1)
19 1 1 0 1 3 45703.0 ± 5465.9 (2)
21 1 1 0 0 2 0 (1)
11 1 1 0 0 2 865.2 (1)
12 1 0 0 1 2 0 (1)
13 1 1 0 0 2 966.2 ± 142.9 (2)
16 1 1 0 0 2 1519.9 (1)
18 1 0 0 1 2 187.4 (1)
23 0 1 0 1 2 5000.0 (1)
22 0 1 0 0 1 3162.3 (1)
24 1 0 0 0 1 8112.3 (1)
*=Values of TNF alpha in pg/mL; Number of measurements are inside parenthesis.
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Nowadays there is much knowledge about TNF alpha
influences in tissue injury. Inflammatory cells and cytokines
cause death by apoptosis both in inflammatory and tissue cells
(pneumocytes, fibroblasts, endothelial, etc.). The extrinsic
pathway of apoptosis is activated by receptors belonging to
the TNF alpha-receptor superfamily. However, Ashkenasi and
Dixit [30] state that TNF alpha rarely starts cellular apoptosis,
unless cellular protein synthesis is blocked. In contrast,
Krammer [31] states that TNF alpha may cause cellular death
by apoptosis, overcoming Rel A protein resistance [32].
Apoptotic cell death caused by TNF alpha may be completely
or partially blocked by NF-kB and its antiapoptotic proteins.
Ciaramella et al. [33] showed that MTB-induced apoptosis
is inhibited by a caspase-1 inhibitor (YVAD) and is associated
with the maturation of IL-1β. In addition, IL-1β and TNF alpha
were produced massively in the course of infection, and both
were inhibited by YVAD. Keane et al. [34] described the
apoptosis of alveolar macrophages infected by M. tuberculosis.
Watson et al. [35] found various pulmonary histopathologic
alterations in different mice species with acute infection by M.
tuberculosis. They suggested that apoptosis occurred during
granuloma formation after infection by M. tuberculosis, through
a FAS/FAS ligand-independent pathway. Taken together, these
studies correlate apoptotic cell death with TNF alpha, and they
highlight the role of this cytokine in TB cases.
One of the objectives of our study was to show that
increased serum TNF alpha was followed by severe clinical
TB with high tissue destruction. On the other hand, we
observed that a decrease in the serum cytokine level occurred
in parallel with patient clinical improvement. We speculate
that a reduction of high TNF alpha serum levels may decrease
tissue destruction, particularly when the cytokine serum level
remains elevated for a long time. TNF alpha periodic
measurements through bioassay or Elisa methods could help
to understand tuberculous outcome and it should be included
in the routine TB clinical evaluation in the near future. However,
in order to establish definitive conclusions more research
should be done. Nowadays the treatment of TB is directed
specifically to M. tuberculosis elimination. We suggest that
TNF alpha immune modulation should be evaluated in
M.tuberculosis therapy in future studies, especially in cases
with very high TNF alpha serum levels.
Table 5. Statistical comparisons of clinical and laboratorial variables related to serum TNF-alpha levels in TB patients.
TNF-α and Severity TB
Variables TNF alpha* p
Patient with TB 13035.54 ± 15948.35 p < 0.01
Control Group 341.3 ± 127.1
Weight loss 1 § 15468.54 ± 4580.54 p < 0.05
Weight loss 0 ¦ 2904.98 ± 1367.89
Thoracic X-Ray 1 15328.48 ± 4602.19 p < 0.05
Thoracic X-Ray 0 3353.18 ± 1495.29
PPD 1 21710 ± 17710 p < 0.05
PPD 0 101.3 ± 101.3
Anemia 1 13592.57 ± 4228.01 p=0.148
Anemia 0 5785.10 ± 2812.07
Fever 1 10799.27 ± 4498.97 p=0.475
Fever 0 16672.10 ± 6521.49
Night sweats 1 11225.22 ± 7789.59 p=0.859
Night sweats 0 12868.47 ± 4306.21
Dyspnea 1 14557.54 ± 5350.22 p=0.514
Dyspnea 0 9703.46 ± 4964.60
Cough 1 10711.0 ± 4916.57 p=0.678
Cough 0 13801.26 ± 5424.93
Sputum 1 6713.95 ± 3083.72 p=0.182
Sputum 0 14782.53 ± 4932.87
VHS 1 16223.23 ± 5634.26 p=0.848
VHS 0 18511.45 ± 9813.49
Tecidual destruction 1 17535.96 ± 5485.07 p=0.149
Tecidual destruction 0 6912.60 ± 4439.29
MR - TB 1 19742.60 ± 18548.71 p=0.695
MR - TB 0 11266.32 ± 3345.66
Recovery 22890.98 ± 11513.85 p=0.352
Death 10026.92 ± 3611.45
*=values of TNF alpha in pg/mL (mean ± standard deviation); MR=Multi-resistant tuberculosis
§ 1=presence of variable; ¦0=absence of variable.
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